Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020
AIM: An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness.
MATERIALS AND METHODS: The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001).
RESULTS: During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics.
CONCLUSION: Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Terapevticheskii arkhiv - 93(2021), 11 vom: 15. Nov., Seite 1306-1315 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Pshenichnaya, N Y [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.10.2022 Date Revised 28.10.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.26442/00403660.2021.11.201206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348011598 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348011598 | ||
| 003 | DE-627 | ||
| 005 | 20231226035200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/00403660.2021.11.201206 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM348011598 | ||
| 035 | |a (NLM)36286653 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Pshenichnaya, N Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2022 | ||
| 500 | |a Date Revised 28.10.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness | ||
| 520 | |a MATERIALS AND METHODS: The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001) | ||
| 520 | |a RESULTS: During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics | ||
| 520 | |a CONCLUSION: Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antiviral therapy | |
| 650 | 4 | |a coronaviruses | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a interferon | |
| 650 | 4 | |a lopinavir | |
| 650 | 4 | |a ritonavir | |
| 650 | 4 | |a umifenovir | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Kareva, E N |e verfasserin |4 aut | |
| 700 | 1 | |a Leneva, I A |e verfasserin |4 aut | |
| 700 | 1 | |a Bulgakova, V A |e verfasserin |4 aut | |
| 700 | 1 | |a Kravchenko, I E |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolaeva, I V |e verfasserin |4 aut | |
| 700 | 1 | |a Grekova, A I |e verfasserin |4 aut | |
| 700 | 1 | |a Ivanova, A P |e verfasserin |4 aut | |
| 700 | 1 | |a Puzyreva, L V |e verfasserin |4 aut | |
| 700 | 1 | |a Khasanova, G M |e verfasserin |4 aut | |
| 700 | 1 | |a Orlova, S N |e verfasserin |4 aut | |
| 700 | 1 | |a Tikhonova, E P |e verfasserin |4 aut | |
| 700 | 1 | |a Petrov, V A |e verfasserin |4 aut | |
| 700 | 1 | |a Malinin, O V |e verfasserin |4 aut | |
| 700 | 1 | |a Kolaeva, N V |e verfasserin |4 aut | |
| 700 | 1 | |a Volchkova, E V |e verfasserin |4 aut | |
| 700 | 1 | |a Kanshina, N N |e verfasserin |4 aut | |
| 700 | 1 | |a Chulanov, V P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Terapevticheskii arkhiv |d 1949 |g 93(2021), 11 vom: 15. Nov., Seite 1306-1315 |w (DE-627)NLM000055425 |x 0040-3660 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2021 |g number:11 |g day:15 |g month:11 |g pages:1306-1315 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26442/00403660.2021.11.201206 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2021 |e 11 |b 15 |c 11 |h 1306-1315 | ||